The Ministry of Health of the Russian Federation approved 151 total clinical studies in Q1 of 2015, which is 11% less than the same quarter last year, though by comparison, it’s still 10 times more than India has approved in the same amount of time.
With an eye on early-phase research, AstraZeneca has signed two deals – a five-year agreement to gain access to PatientsLikeMe’s network, and a three-year alliance with the Lead Discovery Center.
Takeda’s development center in the US has agreed to partner with BioXcel, a cloud-based big data solution provider, to repurpose old medicines to help treat rare diseases.
Computational drug designer Schrödinger has entered into a five-year early drug discovery collaboration with Sanofi in which Schrödinger will provide target analysis and validation to lead identification and lead optimization for as many as ten drug discovery...
London-listed CRO Venn Life Sciences hopes partnering with academics will help generate drug industry interest in its recently expanded skin model tech business.
British MPs have signed an anti-animal cruelty pledge which scientists warn would “cripple” disease research and outlaw 89% of preclinical animal research.
Testing the toxicity of drug candidates in animals is archaic and unreliable according to PETA, which joined preclinical CROs at SOT to put forward alternatives.
Some drug industry sponsors shy away from “jack of all trades” contractors according to a recently formed UK CRO network which says smaller firms with specific expertise can win market share.
Ebola, electronic cigarettes and microbiomes are opportunities for the preclinical research sector according to delegates at a US industry conference this week.
The Broad Institute of MIT and Harvard has entered into a partnership with Calico to study the biology and genetics of aging as part of early-stage drug discovery efforts.
Early phase clinical research service provider Altasciences is forming a strategic alliance with ITR Laboratories, a nonclinical services organization, to help more mutual clients customize their drug development programs from lead candidate selection...
Higher capacity utilization is improving prices across the non-clinical research sector according to Huntingdon Life Sciences CEO Brian Cass, who told Outsourcing-pharma.com the preclinical CRO may add scale to US operations.
For the second straight year Charles River Laboratories has seen more of its revenue derived from biotech companies than Big Pharma, CEO James Foster told investors at two conferences on Tuesday and Wednesday.
Huntingdon Life Sciences has announced it will change its name this year, but has not disclosed what its new moniker will be. So Outsourcing-pharma.com would welcome readers’ suggestions.
Preclinical CRO Crown is acquiring all of Molecular Response’s existing PDX (patient-derived xenograft) models as well as 8,000 viable human tumors for model development.
Charles River Laboratories is nearing the acquisition of an early-stage drug discovery company, CEO James Foster told attendees at the Leerink Swann Global Healthcare Conference last week.
CRO Charles River Laboratories is further exploring the idea of re-opening a preclinical site in Shrewsbury, MA, though it will be more than a year before the site is ready.
Contract research organization (CRO) Horizon has been selected as a “core facility” for supplying biopharma research tools to academic group the Tri-Institutional Therapeutics Discovery Institute.
AstraZeneca has partnered to use the CRISPR genome editing technique across its discovery programmes in a move that puts it on a collision course with French Biotech, Cellectis.
Investment firm William Blair has upgraded preclinical CRO Charles River Laboratories to ‘outperform’ based on strong toxicology demand and the pending acquisition of Covance.
PPD’s recently acquired biotech company X-Chem is launching a multi-target collaboration with Janssen Biotech. Financial terms of the deal were not disclosed.
Horizon says its £6m (€7.7m) purchase of Austrian biotech Haplogen Genomics means it can produce cell lines ten times faster than before using a haploid gene platform.
PPD’s biotech company X-Chem has licensed a second drug discovery program to Bayer Pharma, which follows on a multi-target collaboration the companies established in 2012.
Regulatory reviewers spend more time managing incoming data than on the drug evaluation process, says Instem which has inked a deal with WIL Research for its nonclinical IT systems.
Horizon Discovery Group announced Monday that its bioproduction division has shipped its first commercially available engineered CHO (Chinese Hamster Ovary) cell line for use in manufacturing of antibodies.
Over the last three years US turnover in clinical monitoring has dropped from 29.4% to 16.4% and globally overall company turnover has dropped from 27.2% to 14.2% on average, according to the 16th annual CRO Industry Global Compensation and Turnover Survey.
Evotec and Sanofi have entered into exclusive negotiations for a major strategic partnership that will include a €250m ($310m) minimum guaranteed commitment from Sanofi over the next five years.
A preclinical biotech backed by Bristol-Myers Squibb is forming a strategic alliance with Synergy Partners R&D Solutions to boost academic discoveries.
Ricerca Biosciences has been bought by private equity group Main Market Partners in a deal that means the contract research organisation's (CRO) 199 employees keep their jobs.
Indian CRO GVK BIO announced the signing of a definitive agreement to acquire Vanta Bioscience, a full service preclinical GLP toxicology and safety assessment CRO operating out of Chennai, India.
Lab Corp will buy Covance for $6.1bn in a surprise deal that follows another quarter in which early phase gains were offset by underperformance in central labs.
Weaker demand in Europe and Japan saw revenue from Charles River Laboratories' animal models business decline in Q3, but Argenta and BioFocus boosted discovery sales.
MPI Research announced Monday it has acquired the assets of Kalamazoo, Michigan-based CRO Jasper Clinical Research & Development, which provides early-stage human clinical testing of new drugs for an undisclosed amount.
Horizon is already making plans for the research model company it acquired last month, announcing today it will offer patient-derived xenograft (PDX) models for breast cancer under the Sage Labs name.
Animal-model contract research organisation (CRO) Crown Bioscience will open a research centre in North Carolina, combining expanded oncology services with its existing cardiovascular and metabolic offerings.
MedImmune’s neurodegenerative disease partnership with the University of Cambridge is about working with “great scientists with great brains” according to a spokeswoman for parent company, AstraZeneca.
Thermo Scientific is assessing its PK/PD data analysis software after a technical paper found discrepancies in results that may have affected drug approvals.
Evotec has announced positive milestone news this week, revealing that efforts to develop an endometriosis drug with Bayer have moved into preclinical testing.
Merck KGaA’s acquisition of Sigma-Aldrich is testament to Big Pharma’s growing interest in personalized medicine says Horizon Discovery, which has bought Sage Labs for $48m (€38m).
Newly public Horizon Discovery Group says it is looking for more acquisitions to become a fully integrated products, services and research provider as revenues soars 35%.
